Dr.Nod: computational framework for discovery of regulatory non-coding drivers in tissue-matched distal regulatory elements
暂无分享,去创建一个
[1] P. Campbell,et al. Diverse mutational landscapes in human lymphocytes , 2022, Nature.
[2] Ryan D. Morin,et al. Super-enhancer hypermutation alters oncogene expression in B cell lymphoma , 2022, Nature.
[3] Po-Ru Loh,et al. Genome-wide mapping of somatic mutation rates uncovers drivers of cancer , 2022, Nature Biotechnology.
[4] Sarah E. Williams,et al. Mapping cis-regulatory elements in human neurons links psychiatric disease heritability and activity-regulated transcriptional programs , 2022, Cell reports.
[5] Yanxia Yang,et al. Cyclin D1 mediated by the nuclear translocation of nuclear factor kappa B exerts an oncogenic role in lung cancer , 2022, Bioengineered.
[6] Lin Zhang,et al. Systematic illumination of druggable genes in cancer genomes , 2022, Cell reports.
[7] R. Bhandari,et al. LINC01023 Promotes the Hepatoblastoma Tumorigenesis via miR-378a-5p/WNT3 Axis , 2022, Molecular and Cellular Biochemistry.
[8] M. Hung,et al. Endothelial p130cas confers resistance to anti-angiogenesis therapy , 2020, Cell reports.
[9] E. Larsson,et al. Non-coding driver mutations in human cancer , 2021, Nature Reviews Cancer.
[10] Ryan L. Collins,et al. Genome-wide enhancer maps link risk variants to disease genes , 2021, Nature.
[11] L. Xue,et al. Finding an easy way to harmonize: a review of advances in clinical research and combination strategies of EZH2 inhibitors , 2021, Clinical epigenetics.
[12] Qingfeng Sun,et al. STOML2 potentiates metastasis of hepatocellular carcinoma by promoting PINK1-mediated mitophagy and regulates sensitivity to lenvatinib , 2021, Journal of Hematology & Oncology.
[13] Andrei Barbu,et al. Multi-resolution modeling of a discrete stochastic process identifies causes of cancer , 2021, ICLR.
[14] Xiyong Yu,et al. CKS1B as Drug Resistance-Inducing Gene—A Potential Target to Improve Cancer Therapy , 2020, Frontiers in Oncology.
[15] A. Gonzalez-Perez,et al. A compendium of mutational cancer driver genes , 2020, Nature Reviews Cancer.
[16] Erin L. Schenk,et al. Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing , 2020, Cell.
[17] Hengrui Zhu,et al. PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications , 2020, Molecular Cancer.
[18] Nuno A. Fonseca,et al. Combined burden and functional impact tests for cancer driver discovery using DriverPower , 2020, Nature Communications.
[19] Jun Yu,et al. Analyses of non-coding somatic drivers in 2,658 cancer whole genomes , 2020, Nature.
[20] Mathieu Lupien,et al. Candidate Cancer Driver Mutations in Distal Regulatory Elements and Long-Range Chromatin Interaction Networks. , 2020, Molecular cell.
[21] Icgc,et al. Pan-cancer analysis of whole genomes , 2017, bioRxiv.
[22] Neva C. Durand,et al. Activity-by-Contact model of enhancer-promoter regulation from thousands of CRISPR perturbations , 2019, Nature Genetics.
[23] W. Gong,et al. Knockdown of linc01023 restrains glioma proliferation, migration and invasion by regulating IGF-1R/AKT pathway , 2019, Journal of Cancer.
[24] A. Gonzalez-Perez,et al. Local Determinants of the Mutational Landscape of the Human Genome , 2019, Cell.
[25] H. Jacobs,et al. Mutating for Good: DNA Damage Responses During Somatic Hypermutation , 2019, Front. Immunol..
[26] Ville Mustonen,et al. The repertoire of mutational signatures in human cancer , 2018, Nature.
[27] Wenyu Zhu,et al. Silence of Stomatin-Like Protein 2 Represses Migration and Invasion Ability of Human Liver Cancer Cells via Inhibiting the Nuclear Factor Kappa B (NF-κB) Pathway , 2018, Medical science monitor : international medical journal of experimental and clinical research.
[28] C. Cole,et al. The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers , 2018, Nature Reviews Cancer.
[29] Cameron S. Osborne,et al. Promoter capture Hi-C-based identification of recurrent noncoding mutations in colorectal cancer , 2018, Nature Genetics.
[30] B. Schuster-Böckler,et al. Mutational signature distribution varies with DNA replication timing and strand asymmetry , 2018, Genome Biology.
[31] M. Tomková,et al. DNA Modifications: Naturally More Error Prone? , 2018, Trends in genetics : TIG.
[32] M. Stratton,et al. Universal Patterns of Selection in Cancer and Somatic Tissues , 2018, Cell.
[33] S. Rabbani,et al. Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications , 2018, Front. Oncol..
[34] M. Tomková,et al. DNA Replication and associated repair pathways are involved in the mutagenesis of methylated cytosine. , 2018, DNA repair.
[35] J. Bai,et al. EZH2 promotes hepatocellular carcinoma progression through modulating miR-22/galectin-9 axis , 2018, Journal of experimental & clinical cancer research : CR.
[36] A. Page,et al. Context-Dependent Role of IKKβ in Cancer , 2017, Genes.
[37] Phillip G. Montgomery,et al. Defining a Cancer Dependency Map , 2017, Cell.
[38] F. Supek,et al. Clustered Mutation Signatures Reveal that Error-Prone DNA Repair Targets Mutations to Active Genes , 2017, Cell.
[39] Doron Lancet,et al. MalaCards: an amalgamated human disease compendium with diverse clinical and genetic annotation and structured search , 2016, Nucleic Acids Res..
[40] Ferran Reverter,et al. Discovery of Cancer Driver Long Noncoding RNAs across 1112 Tumour Genomes: New Candidates and Distinguishing Features , 2016, Scientific Reports.
[41] Nicholas A. Sinnott-Armstrong,et al. Noncoding somatic and inherited single-nucleotide variants converge to promote ESR1 expression in breast cancer , 2016, Nature Genetics.
[42] M. Tomková,et al. 5-hydroxymethylcytosine marks regions with reduced mutation frequency in human DNA , 2016, eLife.
[43] J. Chaudhuri,et al. Mutations, kataegis and translocations in B cells: understanding AID promiscuous activity , 2016, Nature Reviews Immunology.
[44] P. Hanawalt,et al. Mutational Strand Asymmetries in Cancer Genomes Reveal Mechanisms of DNA Damage and Repair , 2016, Cell.
[45] A. Valencia,et al. Non-coding recurrent mutations in chronic lymphocytic leukaemia , 2015, Nature.
[46] G. von Heijne,et al. Tissue-based map of the human proteome , 2015, Science.
[47] Paz Polak,et al. Cell-of-origin chromatin organization shapes the mutational landscape of cancer , 2015, Nature.
[48] R. Young,et al. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element , 2014, Science.
[49] Kevin Y. Yip,et al. FunSeq2: a framework for prioritizing noncoding regulatory variants in cancer , 2014, Genome Biology.
[50] W. Hahn,et al. PRKACA Mediates Resistance to HER2-Targeted Therapy in Breast Cancer Cells and Restores Anti-Apoptotic Signaling , 2014, Oncogene.
[51] J. Shendure,et al. A general framework for estimating the relative pathogenicity of human genetic variants , 2014, Nature Genetics.
[52] J. Stamatoyannopoulos,et al. Reduced local mutation density in regulatory DNA of cancer genomes is linked to DNA repair , 2013, Nature Biotechnology.
[53] David T. W. Jones,et al. Signatures of mutational processes in human cancer , 2013, Nature.
[54] D. Leprince,et al. Deciphering HIC1 control pathways to reveal new avenues in cancer therapeutics , 2013, Expert opinion on therapeutic targets.
[55] D. Schadendorf,et al. TERT Promoter Mutations in Familial and Sporadic Melanoma , 2013, Science.
[56] M. Stratton,et al. Deciphering Signatures of Mutational Processes Operative in Human Cancer , 2013, Cell reports.
[57] Chun-Ming Wong,et al. Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis , 2012, Hepatology.
[58] B. Schuster-Böckler,et al. Chromatin organization is a major influence on regional mutation rates in human cancer cells , 2012, Nature.
[59] W. Hall,et al. Intracerebral infusion of the bispecific targeted toxin DTATEGF in a mouse xenograft model of a human metastatic non-small cell lung cancer , 2012, Journal of Neuro-Oncology.
[60] Mei X. Wu,et al. IEX-1 Deficiency Protects against Colonic Cancer , 2012, Molecular Cancer Research.
[61] Prahlad T. Ram,et al. Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death. , 2011, Journal of the National Cancer Institute.
[62] D. Leprince,et al. Differential Regulation of HIC1 Target Genes by CtBP and NuRD, via an Acetylation/SUMOylation Switch, in Quiescent versus Proliferating Cells , 2010, Molecular and Cellular Biology.
[63] Aaron R. Quinlan,et al. BIOINFORMATICS APPLICATIONS NOTE , 2022 .
[64] Rachael P. Huntley,et al. QuickGO: a web-based tool for Gene Ontology searching , 2009, Bioinform..
[65] Morton B. Brown. 400: A Method for Combining Non-Independent, One-Sided Tests of Significance , 1975 .
[66] D. Schadendorf,et al. Highly Recurrent TERT Promoter Mutations in Human Melanoma , 2022 .